IntroductionĬhlorambucil (Clb), an oral alkylating agent, was the mainstay of B-chronic lymphocytic leukemija (CLL) treatments from the fifties. Outcomes seem to be related more to total drug doses than schedules.ī-chronic Lymphocytic Leukemia articles Chlorambucil articles Rituximab articles Lymphoproliferative Disorder articles Article Details 1. Combinations of rituximab and chlorambucil are well tolerated and effective treatments for patients ineligible for fludarabine-based regimens. iClb-R overall survival, progression-free survival and survival without next treatment at 30 mo. Both schedules resulted in similar toxicity and efficacy (cHD-Clb-R vs. One patient stopped treatment due to hepatotoxicity. Most common severe adverse events were granulocytopenia, occurring in 14 and infections in 7 patients, one of whom died. Median age was 66 years (range 41-80) 24 were women and 44 men 24 had Binet stage A, 27 B and 17 C 5 had del(17p). Thirtysix patients received cHD-Clb-R and 32 iClb-R. We performed this retrospective analysis to compare the efficacy and toxicity of continuous high-dose chlorambucil (12-20 mg daily until response or toxicity) (cHD-Clb-R) and intermittent high dose chlorambucil (8-10 mg/m2 daily for 7 days q 4 wk) (iClb-R) in combination with rituximab (375 mg/m2/cycle for 8 cycles) in previously untreated CLL patients. Doses and schedules of this drug vary widely but it is not clear whether this affects outcomes. View / Download Pdf Share at Facebook Abstractĭue to age and comorbidities many patients with CLL receive chlorambucil as front-line treatment. Journal of Cancer Science and Clinical Therapeutics 5 (2021): 426-433. Comparison of Different Schedules of Rituximab and Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia: A Retrospective Study of Krohem. Sandra Bašić-Kinda, Ida Hude, Ena Ranković, Slobodanka Ostojić-Kolonić, Vlatko Pejša, Ivo Radman, Martina Bogeljić-Patekar, Ozren Jakšić, Klara Dubravčić, Ivana Franić-Šimić, Igor Aurer. Received: 18 July 2021 Accepted: 14 September 2021 Published: 01 October 2021 *Corresponding Author: Ena Rankovic, Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, HR-10000 Zagreb, Croatia Sandra Bašic-Kinda 1, Ida Hude 1, Ena Rankovic 1*, Slobodanka Ostojic-Kolonic 2, 3, Vlatko Pejša 2, 4, Ivo Radman 1, Martina Bogeljic-Patekar 2, Ozren Jakšic 2, 4, Klara Dubravcic 1, Ivana Franic-Šimic 1, Igor Aurer 1, 2ġUniversity Hospital Centre, Zagreb, CroatiaĢMedical School, University of Zagreb, Zagreb, CroatiaģUniversity Hospital Merkur, Zagreb, CroatiaĤUniversity Hospital Dubrava, Zagreb, Croatia Comparison of Different Schedules of Rituximab and Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia: A Retrospective Study of Krohem Article Information
0 kommentar(er)
